BioStock: Chordate Medical’s CEO looks ahead to 2025 — “The exit process is our primary focus”

During 2024, Chordate Medical made progress in establishing Ozilia, a drug-free treatment for chronic migraines and nasal congestion. For example, the company expanded its presence in markets such as Switzerland and Saudi Arabia. BioStock has reached out to CEO Anders Weilandt to learn more about the highlights of 2024 and the goals for the coming year.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/12/chordate-medicals-ceo-looks-ahead-to-2025-the-exit-process-is-our-primary-focus/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se